Annukka Vahtera
Overview
Explore the profile of Annukka Vahtera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raatikainen E, Kiiski H, Kuitunen A, Junttila E, Huhtala H, Kallonen A, et al.
J Neurol Sci
. 2024 Feb;
458:122943.
PMID: 38422781
Background And Purpose: Patients with aneurysmal subarachnoid hemorrhage (aSAH) have demonstrated increased blood coagulation which is thought to contribute to delayed cerebral ischemia (DCI) and to a worse outcome. Therefore,...
2.
Parviainen M, Vahtera A, Anas N, Tahtinen J, Huhtala H, Kuitunen A, et al.
Acta Anaesthesiol Scand
. 2022 Jul;
66(9):1083-1090.
PMID: 35908159
Background: Low-molecular-weight heparin enoxaparin is widely used in pharmacological thromboprophylaxis after coronary artery bypass grafting (CABG). The aim of this study was to compare anti-factor X activity (anti-Xa) levels when...
3.
Raatikainen E, Kiiski H, Kuitunen A, Junttila E, Huhtala H, Ronkainen A, et al.
J Neurol Sci
. 2022 Mar;
436:120227.
PMID: 35334421
Background: Although delayed cerebral ischemia (DCI) commonly complicates recovery in survivors of aneurysmal subarachnoid hemorrhage (aSAH), its pathophysiology is incompletely understood. Previous studies examining the association of DCI and platelet...
4.
Raatikainen E, Vahtera A, Kuitunen A, Junttila E, Huhtala H, Ronkainen A, et al.
J Neurol Sci
. 2020 Dec;
420:117261.
PMID: 33316615
Background And Purpose: Delayed cerebral ischemia (DCI) complicates the recovery of approximately 30% of patients with aneurysmal subarachnoid hemorrhage (aSAH). The definition of DCI widely varies, even though a consensus...
5.
Vahtera A, Szanto T, Lassila R, Valkonen M, Sivula M, Huhtala H, et al.
Acta Anaesthesiol Scand
. 2020 Sep;
65(1):109-115.
PMID: 32888192
Introduction: Standard subcutaneous low-molecular-weight heparin (LMWH) thromboprophylaxis yields low anti-factor Xa activity in patients in the intensive care unit (ICU). The aim of the study was to assess coagulation status...
6.
Angus D, Buzgau A, Cheng A, Higgins A, Hullegie S, Lawler P, et al.
JAMA
. 2020 Sep;
324(13):1317-1329.
PMID: 32876697
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, And Participants: An...
7.
Kuitunen A, Sinisalo M, Vahtera A, Hiltunen L, Javela K, Laine O
Transfusion
. 2018 Oct;
58(12):2757-2760.
PMID: 30284726
Background: Heparin-induced thrombocytopenia (HIT) usually appears at 5 to 10 days after initiation of heparin. Autoimmune HIT can arise after discontinuation of heparin treatment (delayed-onset HIT) or without any preceding...
8.
Vahtera A, Valkonen M, Huhtala H, Pettila V, Kuitunen A
Thromb Res
. 2017 Aug;
158:71-75.
PMID: 28846877
Introduction: In intensive care unit (ICU) patients, subcutaneous low-molecular weight heparin thromboprophylaxis results in lower plasma anti-factor Xa (anti-FXa) levels compared to general ward patients. The aim of this study...
9.
Vahtera A, Vaara S, Pettila V, Kuitunen A
Thromb Res
. 2016 Feb;
139:10-6.
PMID: 26916290
Background: Critical care patients are prone to venous thromboembolism (VTE) and, thus, pharmacological thromboprophylaxis is generally advised. Low-molecular weight heparins (LMWHs) have become the drug of choice in ICU patients,...